Kalvista Pharm Stock Price, News & Analysis

KalVista Pharmaceuticals (NASDAQ: KALV) announced the granting of inducement stock options to a newly hired employee. A total of 2,000 shares were issued at an exercise price of $5.10 per share, equivalent to the closing price on November 1, 2022. The options will vest over four years, with 25% vesting after one year and the remainder in monthly increments. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize the new employee's ongoing contribution to the company.

KalVista Pharmaceuticals (NASDAQ: KALV) announced positive Phase 1 results for an orally disintegrating tablet (ODT) formulation of its lead compound, sebetralstat, aimed at treating hereditary angioedema (HAE). The trial involved 36 healthy adult volunteers and indicated a similar pharmacokinetic profile between the ODT and the existing film-coated tablets. The company plans to develop the ODT further and aims for its availability post-launch of sebetralstat. Data from the ongoing Phase 3 KONFIDENT trial is expected in H2 2023, supporting a planned NDA filing in H1 2024.

KalVista Pharmaceuticals announced new data on sebetralstat, published in the Journal of Medicinal Chemistry and Xenobiotica. The research highlights its effectiveness as an on-demand treatment for hereditary angioedema (HAE), showcasing high selectivity against human serine proteases and rapid absorption characteristics, essential for patient needs. Sebetralstat has progressed to Phase 3 KONFIDENT trials, indicating significant advancement towards clinical application. CEO Andrew Crockett expressed optimism about sebetralstat's promise for HAE treatment.

KalVista Pharmaceuticals has announced a significant leadership change, appointing Brian J.G. Pereira, M.D. as the new Chairman of the Board, effective immediately. He replaces Martin Edwards, M.D., who is retiring in a planned transition. Dr. Pereira brings extensive experience in late-stage drug development, crucial for advancing KalVista's lead candidate, sebetralstat, which targets hereditary angioedema (HAE) attacks. The company is currently enrolling participants in the Phase 3 KONFIDENT clinical trial.

KalVista Pharmaceuticals presented new data on patient perspectives regarding treatment outcome measures from the phase 3 KONFIDENT trial of sebetralstat at the 2022 HAEi Global Leadership Workshop. The research showed a strong patient preference for using the Patient Global Impression of Change (PGI-C) scale as a clinical endpoint, with over 70% favoring it over other scales. Additionally, findings highlighted the significant mental health impacts of hereditary angioedema (HAE) on patients, with many missing important life events due to anxiety linked to their condition.

KalVista Pharmaceuticals (NASDAQ: KALV) is under investigation by Holzer & Holzer, LLC for potential violations of federal securities laws. This follows the termination of its KOMPLETE phase 2 clinical trial for KVD824 on October 4, 2022, due to elevated liver enzymes observed in all treatment groups. This announcement resulted in a drop in the company's stock price. Investors who incurred losses on their KalVista stock are encouraged to contact Holzer & Holzer for legal advice regarding their rights.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the granting of inducement stock options to four newly-hired employees, totaling 18,000 shares. These options, priced at $14.24 per share, correspond to the closing stock price on October 3, 2022. They vest quarterly over four years, contingent upon continued employment. KalVista specializes in developing oral small molecule protease inhibitors targeting unmet medical needs, with ongoing clinical trials for treatments in hereditary angioedema and diabetic macular edema.

KalVista Pharmaceuticals (NASDAQ: KALV) has terminated the KOMPLETE Phase 2 clinical trial for KVD824 due to observed elevations in liver enzymes among participants. The company confirmed that these findings do not impact the safety profile of Sebetralstat or the ongoing Phase 3 KONFIDENT trial.

KalVista will focus on advancing Sebetralstat towards a planned NDA filing in 2024 and will prioritize its oral Factor XIIa program for hereditary angioedema (HAE) prophylaxis, aiming for a once-daily therapy.

KalVista Pharmaceuticals (NASDAQ: KALV) has announced the acceptance of multiple abstracts for presentation at the HAE International Global Leadership Workshop in Frankfurt, Germany, from October 6-9, 2022. The presentations focus on patient perspectives regarding optimal treatment outcomes for Hereditary Angioedema (HAE), emphasizing its effects on mental health and quality of life. Notable presentations include a poster on optimal outcome measures and a session on the global impact of HAE attacks. Both presentations are scheduled for October 7 from 2:30-3:30 CET.